145 related articles for article (PubMed ID: 29852134)
1. Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats.
Leong NJ; Mehta D; McLeod VM; Kelly BD; Pathak R; Owen DJ; Porter CJH; Kaminskas LM
J Pharm Sci; 2018 Sep; 107(9):2509-2513. PubMed ID: 29852134
[TBL] [Abstract][Full Text] [Related]
2. Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker.
Mehta D; Leong N; McLeod VM; Kelly BD; Pathak R; Owen DJ; Porter CJH; Kaminskas LM
Mol Pharm; 2018 Oct; 15(10):4568-4576. PubMed ID: 30107748
[TBL] [Abstract][Full Text] [Related]
3. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Owen DJ; Boyd BJ; Porter CJ
J Control Release; 2011 Jun; 152(2):241-8. PubMed ID: 21315119
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy.
Kaminskas LM; McLeod VM; Ryan GM; Kelly BD; Haynes JM; Williamson M; Thienthong N; Owen DJ; Porter CJ
J Control Release; 2014 Jun; 183():18-26. PubMed ID: 24637466
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent.
Ryan GM; Kaminskas LM; Kelly BD; Owen DJ; McIntosh MP; Porter CJ
Mol Pharm; 2013 Aug; 10(8):2986-95. PubMed ID: 23750747
[TBL] [Abstract][Full Text] [Related]
6. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin.
Ryan GM; Kaminskas LM; Bulitta JB; McIntosh MP; Owen DJ; Porter CJH
J Control Release; 2013 Nov; 172(1):128-136. PubMed ID: 23954628
[TBL] [Abstract][Full Text] [Related]
7. Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers.
Haque S; McLeod VM; Jones S; Fung S; Whittaker M; McIntosh M; Pouton C; Owen DJ; Porter CJH; Kaminskas LM
Eur J Pharm Biopharm; 2017 Oct; 119():408-418. PubMed ID: 28713018
[TBL] [Abstract][Full Text] [Related]
8. The interaction of dendrimer-doxorubicin conjugates with a model pulmonary epithelium and their cosolvent-free, pseudo-solution formulations in pressurized metered-dose inhalers.
Zhong Q; Humia BV; Punjabi AR; Padilha FF; da Rocha SRP
Eur J Pharm Sci; 2017 Nov; 109():86-95. PubMed ID: 28774811
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep.
Ryan GM; Bischof RJ; Enkhbaatar P; McLeod VM; Chan LJ; Jones SA; Owen DJ; Porter CJ; Kaminskas LM
Pharm Res; 2016 Feb; 33(2):510-25. PubMed ID: 26486513
[TBL] [Abstract][Full Text] [Related]
10. Capping methotrexate α-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Sberna G; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2011 Apr; 8(2):338-49. PubMed ID: 21171585
[TBL] [Abstract][Full Text] [Related]
11. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.
Kaminskas LM; Kota J; McLeod VM; Kelly BD; Karellas P; Porter CJ
J Control Release; 2009 Dec; 140(2):108-16. PubMed ID: 19686787
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers.
Kaminskas LM; Kelly BD; McLeod VM; Boyd BJ; Krippner GY; Williams ED; Porter CJ
Mol Pharm; 2009; 6(4):1190-204. PubMed ID: 19453158
[TBL] [Abstract][Full Text] [Related]
13. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
[TBL] [Abstract][Full Text] [Related]
14. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
Kaminskas LM; McLeod VM; Kelly BD; Sberna G; Boyd BJ; Williamson M; Owen DJ; Porter CJ
Nanomedicine; 2012 Jan; 8(1):103-11. PubMed ID: 21704192
[TBL] [Abstract][Full Text] [Related]
15. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
[TBL] [Abstract][Full Text] [Related]
16. Partly-PEGylated Poly-L-lysine dendrimers have reduced plasma stability and circulation times compared with fully PEGylated dendrimers.
Kaminskas LM; Wu Z; Barlow N; Krippner GY; Boyd BJ; Porter CJ
J Pharm Sci; 2009 Oct; 98(10):3871-5. PubMed ID: 19283758
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models.
Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ
Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281
[TBL] [Abstract][Full Text] [Related]
18. Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers.
Zhong Q; da Rocha SR
Mol Pharm; 2016 Mar; 13(3):1058-72. PubMed ID: 26832992
[TBL] [Abstract][Full Text] [Related]
19. Conjugation to Poly(amidoamine) Dendrimers and Pulmonary Delivery Reduce Cardiac Accumulation and Enhance Antitumor Activity of Doxorubicin in Lung Metastasis.
Zhong Q; Bielski ER; Rodrigues LS; Brown MR; Reineke JJ; da Rocha SR
Mol Pharm; 2016 Jul; 13(7):2363-75. PubMed ID: 27253493
[TBL] [Abstract][Full Text] [Related]
20. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
